Rebecca Buelt

Mother, Wife, Sister, Daughter, Catholic, Wearable Defibrillator Device Rep

[ZOLL Cardiac Management Solutions @zoll_cms]

At #ACC26, meet the modern LifeVest. The most proven, patient-preferred LifeVest ever delivers:

✅ #1 Patient Compliance: real-world and peer-reviewed data this decade¹⁻³
✅ Incomparable Safety: The lowest inappropriate treatment rate in contemporary literature1
✅ Proven Efficacy: >97% first-shock success⁴⁻⁷

Visit us in Booth 2437 or see our latest innovations: https://t.co/vcF8TttYFh

1 David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, Johann Bauersachs, Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025;, ehaf668, https://t.co/WIJ84vofsd
2 Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268;3 Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.
4 Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation. 2015;132(17):1613–1619.
5 Data on file, 90d0241_a01. Report of AArD Performance during 2019.
6 Data on file, 90a0061_a01_revb. Clinical Evaluation Report for LifeVest Wearable Defibrillator, Model 4000, 2021.
7Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, & Tchou PJ (2010). Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. Journal of the American College of Cardiology, 56(3), 194–203.

[ZOLL Cardiac Management Solutions @zoll_cms]

Does GDMT mitigate early SCA risk?🫀

Recent peer-reviewed data tells us that newly diagnosed NICM and MI/CAD patients remain at risk even with high utilization of GDMT.¹

Join Dr. Hrobwoski-Blackman and Dr. Tomassoni at #ACC26 as they discuss how LifeVest can provide proactive protection for these at-risk patients.

Save the date (March 28) and register now: https://t.co/a2HGBffP12

¹European Heart Journal. https://t.co/JXhxjEEpbK

[ZOLL Cardiac Management Solutions @zoll_cms]

ZOLL LifeVest Goes Red.

During Heart Month and every day of the year, ZOLL supports the cardiology community in providing world-class cardiac care for women with LifeVest®:
• A proven solution, with ~400,000 women protected¹
• Ranks #1 in patient compliance this decade for both women and men (23.4+ hrs/day median in real-world and peer-reviewed studies)² ³ ⁴
• Historically, compliance is higher in women than in men ⁵
• The next generation garment is preferred by patients for even greater comfort⁶
• LifeVest data shows arrhythmias are detected more frequently in women than in men⁵
• Only LifeVest has been studied in peripartum cardiomyopathy.⁷ ⁸
#HeartMonth #GoRedForWomen #LifeVestGoesRed

1 Data on file, 20C1451_a01. Female LifeVest Patient Population January 2026.
2 David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, Johann Bauersachs, Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025;, ehaf668, https://t.co/WIJ84vofsd;
3 Garcia R, Combes N, Defaye P, et al. Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study. EP Europace. 2020;23(1):73-81. doi:10.1093/europace/euaa268;
4 Data on file, 90d0258_a01. 2021 Commercial Compliance Analysis.
5 Kutyifa V, Moss AJ, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry) . Circulation 2015;132(17):1613–1619.
6 Data on file, 20c1184_a01. Garment Comparative Wear Test.
7 Duncker D, Westenfeld R, Konrad T, et al. Risk for life-threatening arrhythmia in newly diagnosed peripartum cardiomyopathy with low ejection fraction: a German multi-centre analysis. Clin Res Cardiol. 2017 Aug;106(8):582-589. doi: 10.1007/s00392-017-1090-5. Epub 2017 Mar 8. PMID: 28275862; PMCID: PMC5529484.
8 Duncker D, Haghikia A, König T, et al. Risk for ventricular fibrillation in peripartum cardiomyopathy with severely reduced left ventricular function-value of the wearable cardioverter/defibrillator. Eur J Heart Fail. 2014 Dec;16(12):1331-6. doi: 10.1002/ejhf.188. Epub 2014 Nov 5. PMID: 25371320.

[Rebecca Buelt @RBuelt76]

Great Day at Carver-Hawkeye Arena

[Rebecca Buelt @RBuelt76]

This is serious business. Come on Hawks! @DBuelt

[ZOLL Cardiac Management Solutions @zoll_cms]

🚨Breaking News🚨 – SCD-PROTECT publication: High SCD risk despite contemporary GDMT across 19,500+ LifeVest patients

@ESC_Journals published the SCD-PROTECT study, addressing a gap in evidence of early SCD risk in the context of four-pillar GDMT for NICM and MI/CAD patients.

📰Read more: https://t.co/EfWwtUSDlI

[ZOLL Cardiac Management Solutions @zoll_cms]

Review key findings from the latest real-world evidence for WCDs presented at recent cardiology conference and understand their implications for early SCD risk in patients on contemporary heart failure therapies.

Presented by Marat Fudim and David Duncker, investigators from SCD-PROTECT.

https://t.co/nk7R0cScCA

[Rebecca Buelt @RBuelt76]

@ChrisDuerr Just beat Rockford!

[Rebecca Buelt @RBuelt76]

@ChrisDuerr @IHSA_IL Together again

[Rebecca Buelt @RBuelt76]

QJHS up at the half in Taylorville 14-10. Quincy showed up!

[ZOLL Cardiac Management Solutions @zoll_cms]

From #THT2025: New data shows that the ZOLL Heart Failure Management System (HFMS) reduces #HF readmission by 29% out to 1-year. Previously published #JACCHF research shows that HFMS helps cardiologists achieve a 38% reduction in 90-day heart failure readmissions. Learn more about ZOLL HFMS: https://t.co/Xrj4wBUfIa

[Rebecca Buelt @RBuelt76]

@ChrisDuerr Congrats young men & Coach @DBuelt !

[Rebecca Buelt @RBuelt76]

@tylerLtomlinson @DBuelt He’s in it : it’s called pj’s! 🤣 I had to get him out of bed to come see who was at the door for him 🫣

[ZOLL Public Safety @ZOLLPublicSfty]

ZOLL® AEDs provide real-time CPR feedback to help anyone save a life. Damar Hamlin @HamlinIsland is raising awareness so communities are ready for emergencies. Discover more at https://t.co/fP03Ffp6sM

[ZOLL Cardiac Management Solutions @zoll_cms]

ZOLL has improved the LifeVest design multiple times over the last 20+ years, leading to a median real-world WearTime® of 23.4 hours/day. Learn about the newest garment: https://t.co/R4LRlR7GV5

[ZOLL Cardiac Management Solutions @zoll_cms]

The results are in: ZOLL Heart Failure Management System (HFMS) was shown to reduce 90-day readmission by 38% following an acute heart decompensation event, per the BMAD Trial, now available in @JACCJournals #JACCHF. https://t.co/5FEtxubqRj #cardiology

[ZOLL Cardiac Management Solutions @zoll_cms]

There is a direct correlation between heart failure hospital readmission and mortality rate. Hear from invasive cardiologist @FahmiJFarah about how she uses ZOLL HFMS in her practice. ZOLL HFMS can reduce 90-day hospital readmissions by 38%. Learn more: https://t.co/o928GSNoRm

[ZOLL Cardiac Management Solutions @zoll_cms]

“One in 3 patients with heart failure after discharge will be readmitted within 90 days. We can intervene and prevent that readmission.” Invasive cardiologist @FahmiJFarah and her patient share how ZOLL HFMS impacted the treatment plan and care path. https://t.co/o928GSNoRm

[ZOLL Cardiac Management Solutions @zoll_cms]

Developed using artificial intelligence, Advanced Arrhythmia Discrimination makes ZOLL LifeVest smarter than ever. See the data: https://t.co/4d1UOnFVqf

[ZOLL Cardiac Management Solutions @zoll_cms]

Heart failure is one of the largest clinical challenges facing healthcare today. New technology from ZOLL has been shown to reduce heart failure readmissions by 38%. See the data and learn more: https://t.co/o928GSNoRm